ABSTRACT. The sp act of galactose-1-phosphate uridyltransferase has been measured in individual regions of adult rat brain to see if site-specific differences in enzyme activity can aid in the understanding of brain abnormalities observed in well-treated galactosemic patients. The sp act in the cerebellum, brain stem, and midbrain were higher than in the cortex, hippocampus, and striatum. Activity in the cerebellum was Zfold greater than that found in the cortex. Steady state levels of mRNA of the enzyme in the cerebellum were twice that of the cortex corresponding to the ratio of enzyme sp act in the two regions. Measurement of the kinetic parameters in tissue from the cerebellum and cortex revealed that the regional specificity in enzyme activity observed in the brain represents differences in the V,.,. Inhibition of the enzyme by uridine and uridine triphosphate was essentially the same for all regions and was not influenced by the 2-fold differences observed in the levels of enzyme. Inhibition by uridine was significantly greater than that for uridine triphosphate. (Pediatr Res 31: 512-515,1992) Abbreviations UDPglucose, uridine diphosphate glucose UDPgalactose, uridine diphosphate galactose UTP, uridine triphosphate SSC, sodium chloride, sodium citrate Abnormal brain function has been a hallmark of the clinical syndrome associated with galactose-1-phosphate uridyltransferase deficiency galactosemia (I). Diminished intelligence and learning disorders (2, 3) and speech defects (4, 5) have been characteristics of the disorder even with early recognition and initiation of a galactose-restricted diet (3). In the stage of acute galactose toxicity, pseudo-tumor cerebri has been reported (6). Despite dietary therapy, many older galactosemic patients exhibit abnormal EEG patterns (2). Recently, there have been a number of reports (7-10) of the development of ataxic neurologic abnormalities in older children and adults indicative of cerebellar dysfunction. Indeed, Bohles et al. (9) described atrophy of the cerebellum, brain stem, and basal ganglia by computerized tomography.
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There have only been rare descriptions of the neuropathologic findings of the brain of patients with galactosemia. Both Crome Supported by National Institutes of Health Grant DK 42785.
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(13) described degenerative changes of cerebellar Purkinje cells in a 4-mo-old infant succumbing to the disease. These findings suggested that the regional brain alterations in galactosemia may be related to the site-specific loss of galactose-1-phosphate uridyltransferase activity. We have, therefore, examined the sp act of this enzyme in several regions of the rat brain to determine if differences in activity of the enzyme correspond to regions of the brain clinically affected in the human disorder. We have found that the sp act of the enzyme is high in brain stem, midbrain, and cerebellum, which has nearly twice the level of cortex. Also, the steady state mRNA level of the enzyme closely parallels the enzymatic activity of the latter two regions.
MATERIALS AND METHODS
Sprague-Dawley rats, from Charles River Breeding Farms (Wilmington, MA), were housed three per cage in a room with a light/dark cycle of 10: 14 h where all animals had free access to food and water. Tissue from exsanguinated animals was dissected on an ice-cold surface. Individual regions of the brain were quickly frozen between blocks of dry ice and stored at -76°C for enzyme analysis and RNA isolation. White matter was separated from the cortex and the gray matter-enriched fraction retained for analysis. Biochemicals were purchased from Sigma Chemical Co. (St. Louis, MO), radiolabeled ['4C]~-galactose-l-phosphate was obtained from New England Nuclear (Boston, MA), and uridine diphosphate ['4C]glucose from Amersham (Arlington Heights, IL). The ion exchange paper, diethylaminoethyl cellulose, was a product of Whatman Inc. (Clifton, NJ).
The measurement of the sp act of galactose-l -phosphate uridyltransferase was based on the radioisotope method of Bertoli and Segal (14) , which has been used in a series of reports from this laboratory (1 5-1 7). Cell-free hornogenates were prepared by Radiolabeled substrates and the corresponding products were separated by chromatography, and their respective areas counted in liquid scintillation fluid. Protein concentrations were determined using the Coomassie blue reagent and protein standard supplied by Bio-Rad (Richmond, CA). Enzyme sp act are expressed as nmol of product formed per min per mg soluble protein.
The apparent Michaelis-Menten constants were measured using Lineweaver-Burk plots (1 8) glucose was fixed when galactose-I-phosphate was varied. Total RNA were prepared by the method of Chomczynski and Sacchi (19) . RNA was isolated by homogenizing 100 mg of frozen tissue with I mL of 4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7), 0.5% SDS, and 0.1 M 2-mercaptoethanol. The following were added sequentially: 0.1 mL of 2 M sodium acetate (pH 4), 1 mL of water-saturated phenol, and 0.2 mL of chloroform-isoamyl alcohol (49: 1) with thorough mixing after each addition. The mixture was centrifuged at 10 000 x g for 20 min, the supernatant removed, and the RNA precipitated at -20°C for 1 h with 1 mL of isopropanol. The RNA was dissolved in 0.5% SDS and the concentration determined by absorption at 260 nm UV. Ten pg of total RNA were electrophoresed through a 1 % agarose-formaldehyde gel (20) using 0.24-to 9.5-kb RNA size markers (BRL, Bethesda, MD) as standards. The RNA was transferred to a Zetabind membrane (CUNO) by capillary blotting using 10 x SSC for 24 h and was UV-crosslinked to the membrane using a UV-Stratalinker 1800 (Stratagene).
A 786-bp rat transferase cDNA (unpublished data) was radio- 
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XAR-2 film at -70'C. Densitometry scans were obtained using a LKB Ultroscan XL enhanced laser densitometer and analyzed using LKB Gelscan XL software (LKB Instruments Inc., Gaithersbura. MD).
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~hetransfkrase probe was stripped from the Northern blot by boiling in water. The blot was then prehybridized as above, and lo6 cpm of end-labeled rat 18s ribosomal RNA probe were 18s -added and allowed to hybridize for 16 h. The blot was washed as above and autoradiographed at -70°C for 4 h followed by densitometry scanning.
Data is presented as the average + SEM for n = five to 11 animals. The t test for paired data was used to determine levels of significance where p < 0.05 is considered significant.
RESULTS
Regional activity of galactose-1-phosphate uridyltransferase. The sp act of galactose-I-phosphate uridyltransferase in six brain regions is shown in Figure 1 . The highest sp act is found in the cerebellum with a mean + SEM of 9.05 + 0.18 nmol/min/mg protein (n = lo), whereas the cortex, striatum, and hippocampus had lower levels of 4.96 + 0.18, 4.25 + 0.25, and 4.69 + 0.32, respectively. These differ significantly from the cerebellum ( p < 0.001). The sp act of midbrain of 8.19 + 0.66 (n = 11) did not differ significantly from cerebellum or brain stem, 7.16 k 0.50 (n = 1 1). The latter value, although only 2 1 % lower, differed from the cerebellum with a p < 0.05. mRNA expression of galactose-I-phosphate uridyltransferase. Figure 2 shows the autoradiograms of the Northern blots from cortex and cerebellum from three animals. Three bands are visible in each of the uridyltransferase lanes. The lower band, which is the major species, corresponds to the 1.4-kb mRNA expected for rat uridyltransferase (unpublished data) and is similar in size to the human mRNA (21) . In addition to the major mRNA species, two minor bands, approximately 1.6 and 2 kb in size, are present in all three animals. The identity of these Fig. 2 . Hybridization of 32P-labeled 786-bp rat transferase cDNA and rat 18s ribosomal oligonucleotide to total RNA from rat brain cortex and cerebellum. Autoradiography was performed with Kodak XAR-2 for 4 d (lanes 1-4) or 5 d (lanes 5 and 6) . Galactose-I-phosphate uridyltransferase mRNA (LIT) and rat 18s ribosomal RNA (18s) from the cortex and cerebellum of a single animal are presented in adjacent lanes; Iana 1 and 2 correspond to the cortex and cerebellum, respectively, from animal number I; lanes 3 and 4 represent these regions from a second animal; lanes 5 and 6 those from the third. bands is unknown, but they may represent either transferase premRNA or mRNA for an enzyme(s) with significant homology to transferase. The presence and intensity of these bands is variable between different tissues (unpublished data). Figure 3 is a graphic representation of the densitometry analysis of the data in Figure 2 . The ordinate units represent Gaussian areas under the densitometry curves, which have been standardized to rat 18s ribosomal RNA. The average ratio of areas of cerebellum to cortex is 2.16 for three animals. The ratio of uridyltransferase sp act of the two regions as shown in Figure I is 1.82.
Kinetics of transferase in cerebellum and cortex. Because the cerebellum and cortex are areas of the brain known to be involved in the neurologic disturbances occumng in galactosemia, these regions were examined in further detail to determine the kinetic basis of the site-specific differences observed in the sp act of the enzyme. These data are represented as double recip-ROGERS ET AL. rocal plots shown in Figures 4 and 5 , where linear regression analysis of the data was used to compute the apparent MichaelisMenten constants given in Table 1 . No differences were found for the apparent Km; however, the apparent V,,, with respect to both substrates was significantly higher for the cerebellum.
Enzyme modulation. A previous report examining the effects of modulators on the enzyme activity in homogenates of whole rat brain showed that uridine and UTP are inhibitors of enzyme activity at concentrations as low as 0.05 mM (22) . We, therefore, examined the effects of these inhibitors on activity in each region of the brain to determine if the site-specific differences observed in enzyme activity relate to the degree of inhibition by uridine and UTP. Inhibition by uridine varied from 37 to 46%. Regions with high transferase were not significantly inhibited more than those with low enzyme activity (Fig. 6) . The percentage of inhibition by UTP was lower than that observed for uridine, 
DISCUSSION
The analysis of regional distribution of galactose-1-phosphate uridyltransferase activity in rat brain demonstrates that the cerebellum, midbrain, and brain stem have the highest levels. The data indicate that the higher enzyme sp act of the cerebellum compared with cortex is paralleled by a comparable difference in steady state mRNA level. These results suggest a genetic control mechanism is operative to maintain higher amounts of enzyme in the cerebellum. The kinetic analysis showing a greater V,,, for cerebellum than cortex without alteration in the Km is consistent with there being more enzyme protein in cerebellum.
Because the brain is a multifunctional organ, the finding of regional specificity for enzyme activity is not unusual. Litteria and Popoff (23) have reported that rat brain uridine kinase is highest in cerebellum. The activity of 11-/3-hydroxysteroid dehydrogenase activity in cerebellum is also high and, like uridyl- transferase, mRNA expression correlates with the enzyme activity (24) . Because we examined whole cerebellum or brain regions grossly, we have no knowledge of the enzyme distribution in various cellular elements in these areas. Dagani et al. (25) , however, have reported data on a variety of enzyme activities in subcellular fractions of rat brain cortex and cerebellum. Citrate synthase activity was higher in cerebellar mitochondria, and cytochrome oxidase was higher in a cerebellar synaptosome fraction. Lowry et al. (26) have shown human cerebellar pyruvate kinase and citrate synthase activity to be higher than that in cerebral cortex.
Our knowledge of galactose metabolism in these regions is insufficient to postulate why some regions of the brain might require higher levels of this enzyme. One possibility is the need to maintain a sufficient pool size of UDPgalactose, the product of the transferase reaction with galactose-1-phosphate and UDPglucose, which is required to synthesize complex glycoproteins and galactolipids. Both a deficiency of UDPgalactose (27) and evidence for a galactosylation defect in galactosemic cells (28, 29) have been suggested as a basis of long-term complications of galactosemia.
Because uridine administration has been advocated as a preventive measure for lone-term com~lications of galactosemia (30), we have investigatedYthe effects df uridine and z s metabolic product UTP on galactose-1 -phosphate uridyltransferase activity in rat liver (3 I), oiar-y, and whole rat brain (22) . Both compounds inhibit the enzyme at relatively low concentrations where the effects are additive. The present findings demonstrate that uridine and UTP inhibit transferase activity to the same extent in various brain regions without regard to the differences in enzyme activity. Because Litteria and Popoff (23) have reported that rat brain uridine kinase is highest in cerebellum, the administration of uridine could lead to conversion to UTP, as we have found in the liver (31) , with the possibility of a greater abundance in cerebellum than elsewhere. Such a phenomenon would suggest a possible detrimental aspect to uridine administration in galactosemic patients, in whom residual transferase activity could be inhibited (21) .
Although mental retardation has been a prominent finding in classic galactosemic patients, in whom this enzyme is deficient (1-3) , an additional feature has been a neurologic syndrome of cerebellar dysfunction (7) (8) (9) (10) . Indeed, in several reports of computed tomography or magnetic resonance imaging examinations of such patients, cerebellar alterations have been described (9, 10) . In addition, in a limited number of autopsy examinations of galactosemic brains, brain stem and cerebellar atrophy have been found with disruption of the cerebellar Purkinje cell layer (9-1 1) . Such findings taken in conjunction with the regional distribution of the involved enzyme in rat brain lead us to speculate that the loss of the high enzyme activity in the cerebellum may make that region particularly vulnerable to the resulting abnormality of galactose metabolism.
